Abstract
The rapidly increasing prevalence of type 2 diabetes (T2D) is motivating an intensive search for biomarkers to identify individuals at risk for developing the disease. It has been established that both genetic and environmental factors are influential in the progression to T2D. Currently, the number of genetic loci implicated in T2D susceptibility is more than 65 and together, these factors explain only about 10% of the risk. At this time, prediction models using genetic information do not perform substantially better than models based on routine clinical measures. The search for new biomarkers must integrate new, independent factors beyond the static genome that are influenced by environmental conditions. This search must also recognize the heterogeneity of T2D and seek new biomarkers of potential subtypes and confounding conditions such as obesity. Modulation of gene expression by epigenetic modifications and the action of microRNAs are being recognized as critical processes affecting T2D risk. This review provides an update on the current state of genetic biomarkers of T2D susceptibility and examines how epigenetic modulation of some new and established diabetes susceptibility genes can identify increased risk and provide biomarkers for early detection and therapeutic monitoring.
Keywords: Diabetes, pre-diabetes, genetics, epigenetics, microRNA, GWAS, biomarker.
Current Diabetes Reviews
Title:DNA Methylation and MicroRNA-Based Biomarkers for Risk of Type 2 Diabetes
Volume: 12 Issue: 1
Author(s): Thomas M. O’Connell and Christina A. Markunas
Affiliation:
Keywords: Diabetes, pre-diabetes, genetics, epigenetics, microRNA, GWAS, biomarker.
Abstract: The rapidly increasing prevalence of type 2 diabetes (T2D) is motivating an intensive search for biomarkers to identify individuals at risk for developing the disease. It has been established that both genetic and environmental factors are influential in the progression to T2D. Currently, the number of genetic loci implicated in T2D susceptibility is more than 65 and together, these factors explain only about 10% of the risk. At this time, prediction models using genetic information do not perform substantially better than models based on routine clinical measures. The search for new biomarkers must integrate new, independent factors beyond the static genome that are influenced by environmental conditions. This search must also recognize the heterogeneity of T2D and seek new biomarkers of potential subtypes and confounding conditions such as obesity. Modulation of gene expression by epigenetic modifications and the action of microRNAs are being recognized as critical processes affecting T2D risk. This review provides an update on the current state of genetic biomarkers of T2D susceptibility and examines how epigenetic modulation of some new and established diabetes susceptibility genes can identify increased risk and provide biomarkers for early detection and therapeutic monitoring.
Export Options
About this article
Cite this article as:
M. O’Connell Thomas and A. Markunas Christina, DNA Methylation and MicroRNA-Based Biomarkers for Risk of Type 2 Diabetes, Current Diabetes Reviews 2016; 12 (1) . https://dx.doi.org/10.2174/1573399811666150515125557
DOI https://dx.doi.org/10.2174/1573399811666150515125557 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
ENaC Modulators and Renal Disease
Current Molecular Pharmacology MicroRNAs as Candidate Drug Targets for Cardiovascular Diseases
Current Drug Targets Bioprocess and Bioreactor: Next Generation Technology for Production of Potential Plant-based Antidiabetic and Antioxidant Molecules
Current Medicinal Chemistry Animal Models of Diabetes Mellitus: Relevance to Vascular Complications
Current Pharmaceutical Design Vascular Endothelial Dysfunction and Nutritional Compounds in Early Type 1 Diabetes
Current Diabetes Reviews Targeting Chromatin Remodeling to Prevent Cardiovascular Disease in Diabetes
Current Pharmaceutical Biotechnology Antidiabetic Effect of Polyphenolic Extracts from Selected Edible Plants as α-Amylase, α -Glucosidase and PTP1B Inhibitors, and β Pancreatic Cells Cytoprotective Agents - A Comparative Study
Current Topics in Medicinal Chemistry Nucleic Acid-Based Aptamers: Applications, Development and Clinical Trials
Current Medicinal Chemistry Heparanase: Structure, Biological Functions, and Inhibition by Heparin-Derived Mimetics of Heparan Sulfate
Current Pharmaceutical Design Classical and New Renin-Angiotensin Signalling in Atherosclerosis
Current Signal Transduction Therapy Biology of Circulating Nucleic Acids and Possible Roles in Diagnosis and Treatment in Diabetes and Cancer
Infectious Disorders - Drug Targets Prognostic Value of Copeptin in Chronic Kidney Disease: From General Population to End-Stage Renal Disease
Current Protein & Peptide Science New Inhibitors of Glycogen Phosphorylase as Potential Antidiabetic Agents
Current Medicinal Chemistry Editorial (Should Chronic Kidney Disease be Considered as a Coronary Heart Disease Equivalent?)
Current Vascular Pharmacology Therapeutic Targeting of Endothelial Dysfunction in Chronic Diabetic Complications
Recent Patents on Cardiovascular Drug Discovery Renal Function, Albumin-Creatinine Ratio and Pulse Wave Velocity Predict Silent Coronary Artery Disease and Renal Outcome in Type 2 Diabetic and Prediabetic Subjects
Current Hypertension Reviews Endothelial Function Assessment in Complicated Hypertension
Current Pharmaceutical Design Discovery of 6-Deoxydapagliflozin as a Highly Potent Sodium-dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes
Medicinal Chemistry Epigenetic Regulation Through SIRT1 in Podocytes
Current Hypertension Reviews Role of Sulfur Containing Amino Acids as an Adjuvant Therapy in the Prevention of Diabetes and its Associated Complications
Current Diabetes Reviews